Oxford Biomedica PLC Total Voting Rights (1367Y)
01 December 2017 - 9:16PM
UK Regulatory
TIDMOXB
RNS Number : 1367Y
Oxford Biomedica PLC
01 December 2017
Oxford BioMedica
Total Voting Rights
Oxford, UK - 1 December 2017: Oxford BioMedica plc ("Oxford
BioMedica" or "the Company") (LSE: OXB), announces that in
accordance with the FCA's Disclosure and Transparency Rule 5.6.1,
the Company's issued share capital as at the close of business on
30 November 2017 consisted of 3,107,136,542 ordinary shares of 1
pence each ("Ordinary Shares"). There are no Ordinary Shares held
in treasury.
Accordingly, the total number of voting rights in Oxford
BioMedica plc at the date of this notice is 3,107,136,542.
The above figure (3,107,136,542) may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, Oxford BioMedica plc under the FCA's Disclosure
and Transparency Rules.
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Stuart Paynter, Chief Financial
Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/Philippa 3709 5700
Gardner/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and ex
vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, Orchard
Therapeutics and Immune Design, through which it has long-term
economic interests in other potential gene and cell therapy
products. Oxford BioMedica is based across several locations in
Oxfordshire, UK and employs more than 280 people. Further
information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREAEAFEFLXFFF
(END) Dow Jones Newswires
December 01, 2017 05:16 ET (10:16 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024